Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to ...

(Reuters) -Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.